All In Biotech

Drug Trial Radar · NCT07344376

An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)

An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) in Patients With Hunter Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

30

Actual

Start

May 23, 2018

Primary completion

Dec 30, 2022

Study completion Dec 30, 2022

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
Collaborators
Samsung Medical Center
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months

Conditions

  • MPS II
  • Hunter Syndrome (MPS II)
  • Hunter Syndrome
  • Hunterase
  • GC1111

Interventions

  • HunteraseDrug

    0.5mg/kg weekly IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Laboratory tests (CBC, Chemistry, Urinanalysis)Time frame: Every visit until 12months
  2. Physical examinationTime frame: Every visit until 12months
  3. Adverse EventTime frame: Every visit until 12months
  4. ElectrocardiographyTime frame: Every 6 months until 12months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.